+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07080567

Phase 2 Trial Comparing Maraviroc to Placebo to Improve Motor Skills After Ischemic Stroke

Led by Emmanuel Carrera · Updated on 2025-08-12

80

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of Maraviroc, a drug that blocks the CCR5 receptor, to see if it can improve motor function and learning skills in patients during the first three months after an ischemic stroke. This phase II randomized controlled trial compares Maraviroc to a placebo in patients who have recently experienced a stroke, aiming to enhance recovery where current stroke treatments still leave many with lasting disabilities. Participants will be randomly assigned to receive either Maraviroc at a dose of 300 mg twice daily or a placebo Mannitol for 90 days. The study is double-blinded, meaning neither the patients nor the researchers know who is receiving the active drug or placebo. Brain images and motor learning tasks will be conducted at the start and end of the treatment period to assess changes. Throughout the 90-day treatment, patients will undergo clinical evaluations, motor tests, and biometric assessments. Follow-up continues at six months after stroke onset to monitor progress. The primary outcome measured is the Upper Extremity Fugl-Meyer Assessment score on day 90, which evaluates motor function recovery. Safety will be monitored by recording adverse events during and after treatment.

CONDITIONS

Brief Title

Manipulating the Peri-Infarct Area Using Maraviroc to Enhance Motor Skills After Stroke

Research Team

E

Emmanuel Carrera, MD

N

Nicolas Broc, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here